Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update

Thursday, October 31, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals, Inc. has announced it will release its financial results for the third quarter of 2024 after market close on November 7, 2024. Following the announcement, the company will host a live conference call and webcast to discuss the results and provide a business update. Participants can access the call via dial-in or through the company's website, where the replay will be available for 90 days. Rigel focuses on developing therapies for cancer and hematologic disorders.
Price reaction · baseline $14.27 (2024-10-30 close) · hit after-hours · 1 other RIGL headline(s) in the window, move may be shared
day 0 close · peak
-4.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel will report third-quarter financial results, indicating active business operations.
  • Live conference call allows for direct engagement with management about business updates.
  • Webcast will be archived, providing long-term access to information for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.
Contact for Investors & Media:
Rigel Pharmaceuticals, Inc.
Email: [email protected]

Frequently Asked Questions

When will Rigel announce its Q3 2024 financial results?

Rigel will announce its Q3 2024 financial results on November 7, 2024.

How can I access Rigel's conference call?

Participants can join the call by dialing 877-407-3088 or 201-389-0927.

Where can I find the webcast of the financial results?

The webcast will be available on the Investor Relations section of Rigel's website.

How long will the webcast be available for replay?

The webcast will be archived and available for replay for 90 days.

What is Rigel Pharmaceuticals focused on?

Rigel Pharmaceuticals focuses on developing therapies for hematologic disorders and cancer.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare third quarter results financial update biotechnology conference call
Last updated: Oct 31, 2024

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →